桑白皮汤加减对肺胀急性发作期痰热蕴肺证临床研究.pdfVIP

疗后两组症状比较：治疗组咳嗽、痰色、喘息、脉象有明显差异 （P0.05），气短、舌苔及临床症状总积分存在显著性差异（P0.01）， 证明治疗组患者各症状体征的改善明显好于对照组症状改善。血白细 胞治疗组治疗前后比较P0.01 ，对照组治疗前后比较P0.05 ；(3)治 疗组与对照组组间治疗后血白细胞总数比较有显著差异P0.05 ；两组 中性粒细胞比率治疗后比较与治疗前组内比较均有显著差异（* P0.05 ），但是两组间比较无明显差异。说明桑白皮汤加味治疗组对 白细胞的转归影响优于对照组，而对中性粒细胞比率的影响治疗组与 对照组相比无明显差异。 (4)治疗组与对照组病例肺功能治疗前后比 较（P＞0.05)，说明两组病例治疗前后组内及组间均无差异，没有统 计学意义。说明在观察期限内桑白皮汤加减方组与对照组的治疗对肺 功能的改善无显著效果，桑白皮汤加减方组对肺功的影响不比对照组 好。 结论：本次临床研究结果表明，桑白皮汤加减方可以明显改善 AECOPD 患者的总疗效、临床症状，白细胞的转归；但（对）治疗期 间对肺功能的影响不比对照组好。在服药过程中，对肝肾功能及血尿 常规无明显影响，临床疗效显著，无明显不良反应，是一种安全有效 的治疗方法。 关键词：肺胀；AECOPD； 桑白皮汤加减方； 痰热蕴肺证；临床症状；白细胞转 归；临床研究 3 Abstract Objective: This subject aims to sangbaipi Decoction the AECOPD Tanreyunfei retention syndrome clinical studies to observe the clinical efficacy in patients with AECOPD, the outcome of the white blood cells and neutrophils and pulmonary function. sangbaipi Decoction lung inflation attack of (AECOPD) provide the basis for the treatment of patients with the role of sangbaipi Decoction the clinical treatment of patients with lung inflation attack of (AECOPD). Methods: 80 cases of Tanreyunfei retention in the lung syndrome met the inclusion criteria of chronic obstructive pulmonary disease with acute exacerbation (lung inflation exacerbation of) were randomly assigned to the treating and control groups: control group of 40 patients given controlled oxygen, ceftazidime (right ceftazidime allergy were given cefoperazone sulbactam, or azithromycin), with levofloxacin resistance to infection; wheezing were given aminophylline, thick sputum difficult to spit were given ambroxol hydrochloride; treatment group of 40 patients given oral sangbaipi Decoction with Western medical treatment; observation of clinical symptoms, WBC and neutrophil rat